Author : adminDate : 2023-02-02 10:21

HLB's anticancer drug receives greenlight in China

The combination use of Jiangsu Hengrui Medicine’s camrelizumab and HLB Bio’s rivoceranib has received a novel drug approval from the National Medical Products Administration of China, HLB Bio announced Wednesday. 

Please refer to the following website for further details: